Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pharmather Hldgs Ltd
(OP:
PHRRF
)
0.1550
-0.0051 (-3.19%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pharmather Hldgs Ltd
< Previous
1
2
Next >
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.
Via
Benzinga
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
October 02, 2023
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...
Via
Benzinga
PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
September 27, 2023
The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings’ (OTCQB: PHRRF) new drug application for a racemic ketamine product.
Via
Benzinga
Exposures
Product Safety
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
September 12, 2023
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
Via
Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
September 11, 2023
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
September 06, 2023
Specialty biotech company PharmaTher Holdings (OTCQB: PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, t
Via
Benzinga
Exposures
Product Safety
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
July 24, 2023
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal...
Via
Benzinga
PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
July 18, 2023
PharmaTher Holdings (OTCQB: PHRRF) and the Terasaki Institute for Biomedical Innovation evaluated the former’s novel microneedle patch for the delivery of DMT, and research yielded positive outcomes.
Via
Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
June 28, 2023
Psychedelics biotech BetterLife Pharma Inc. (OTCQB: BETRF) is fast-tracking its U.S.
Via
Benzinga
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
June 27, 2023
Specialty biotech company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic...
Via
Benzinga
PharmaTher's Novel Ketamine Heads For The US Market With New Collaboration Agreement
June 20, 2023
Psychedelics biotech PharmaTher Holdings (OTCQB: PHRRF) has entered into a collaborative partnership with pharma marketing company Vitruvias Therapeutics for the commercialization of its proprietary...
Via
Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
May 08, 2023
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
Via
Benzinga
Parkinson's Patients May Benefit From Ketamine, PharmaTher Applies For FDA Fast Track
May 03, 2023
Specialty pharmaceutical company PharmaTher Holdings (OTCQB: PHRRF) has submitted a Fast Track Application to the Food and D
Via
Benzinga
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
April 05, 2023
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin...
Via
Benzinga
MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update
April 03, 2023
Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to...
Via
Benzinga
Ketamine Company Advances Parkinson's Treatment Through Final Stages Toward FDA Approval
March 30, 2023
PharmaTher Holdings Ltd.
Via
Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
February 27, 2023
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and...
Via
Benzinga
Development Of DMT Transdermal Patch With Eye Disease Treatment In Mind
February 22, 2023
Specialty R&D psychedelics company PharmaDrug Inc. (OTCQB: LMLLF) has inked a research collaboration agreement with PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) to evaluate the delivery of DMT through...
Via
Benzinga
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
February 13, 2023
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More
Via
Benzinga
PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation
February 07, 2023
Specialty ketamine company PharmaTher Holdings Ltd.
Via
Benzinga
Psyched: Australia Legalizes Psychedelics Therapy, BC's Decrim, State Bills, Millions For Trials & Clinics
February 06, 2023
Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically...
Via
Benzinga
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
February 06, 2023
Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve
Via
Benzinga
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
February 03, 2023
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.
Via
Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
January 25, 2023
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?
Via
Benzinga
Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News
January 21, 2023
Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for...
Via
Benzinga
Psychedelics Market Could Reach $12B By 2029, Says New Report
January 19, 2023
A new analysis of the global market for psychedelics performed by Brandessence Market Research shows an expected growth from 2022’s $4.87 billion to an annual valuation of nearly $12 billion before...
Via
Benzinga
2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products
January 11, 2023
Two psychedelics companies have shared their updates and key milestones to be reached this 2023.
Via
Benzinga
FDA OKs Ketamine For Treating Organ Transplant Injuries With 'Orphan Drug' Status
December 15, 2022
The U.S. Food and Drug Administration (FDA) has granted PharmaTher Holdings Ltd. (OTCQB: PHRRF) an Orphan Drug designation for ketamine in the prevention of injury from organ transplantation.
Via
Benzinga
Ketamine Could Soon Be A Treatment Option For This Rare Genetic Neurological Disorder
November 01, 2022
Specialty biopharma company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has entered into an evaluation and exclusive option agreement with Case Western Reserve University (CWRU)
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.